Drug Profile
Trevogrumab - Regeneron Pharmaceuticals
Alternative Names: REGN-1033; SAR-391786Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; Sanofi
- Class Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Sarcopenia
- No development reported Musculoskeletal disorders; Osteoporosis
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Osteoporosis in USA (Parenteral)
- 28 Feb 2020 No recent reports of development identified for phase-I development in Musculoskeletal-disorders(Combination therapy, In volunteers) in New Zealand
- 20 Sep 2019 Preclinical trials in Osteoporosis in USA (Parenteral) before September 2019